The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global neuroendovascular coil market size reached US$ 928.1 Million in 2021. Looking forward, IMARC Group expects the market to reach US$ 1,182.7 Million by 2027, exhibiting a growth rate (CAGR) of 4% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Neuroendovascular coiling is a minimally invasive endovascular treatment which is performed to block the blood flow in a blood vessel in the brain. It is essential to treat an aneurysm, a bulge caused by weakness in the wall of a blood vessel, which can rupture due to rising pressure and bleed into the brain. The symptoms of a ruptured aneurysm generally include sudden onset of a severe headache, nausea, vomiting, blurred or double vision, and seizure. In neuroendovascular coiling, a surgeon tightly packs the aneurysm with detachable platinum coils that promote blood clotting and reduce pressure on the outer wall. Neuroendovascular coiling is becoming popular across the globe as it incurs less cost and lowers the risk for the patients.
Several advances have been made in the neuroendovascular coil technology in terms of shape, length and bioactivity. Besides this, significant progress has been made in intracranial stents to improve their deployment and delivery. Surgeons have started integrating intracranial stents with the coil technology to treat aneurysms and reduce issues related to recurrence. Moreover, endovascular coiling is being considered a better surgical technique than clipping regarding postoperative complications, favorable outcomes and rehabilitation. Other than this, various market players are investing in the introduction of technologically advanced products. For instance, in 2018, Cerenovus, a division of the Johnson & Johnson Medical Devices Companies, launched the Galaxy G3 Mini embolic coil which is designed to have an irregular shape to enable the device to fill open spaces in cerebral aneurysms.
IMARC Group’s latest report provides a deep insight into the global neuroendovascular coil market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the neuroendovascular coil market in any manner.
IMARC Group provides an analysis of the key trends in each sub-segment of the global neuroendovascular coil market report, along with forecasts at the global and regional level from 2022-2027. Our report has categorized the market based on product type, indication, application and end user.
Breakup by Product Type:
Breakup by Indication:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being Medtronic, Stryker Corporation, DePuy Synthes, Penumbra, Johnson & Johnson Services Inc., Terumo Corporation, Cardinal Health, Boston Scientific Corporation, Cook Medical Incorporated, Balt Extrusion, EndoShape, etc.
|Base Year of the Analysis||2021|
|Segment Coverage||Product Type, Indication, Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Companies Covered||Medtronic, Stryker Corporation, DePuy Synthes, Penumbra, Johnson & Johnson Services Inc., Terumo Corporation, Cardinal Health, Boston Scientific Corporation, Cook Medical Incorporated, Balt Extrusion and EndoShape|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at